id: topiramate_treatment_to_liver_injury_markers
name: Topiramate Pharmacotherapy â†’ Liver Injury Markers (Gamma-glutamyltransferase)
from_node:
  node_id: topiramate_treatment
  node_name: Topiramate Pharmacotherapy
to_node:
  node_id: liver_injury_markers
  node_name: Liver Injury Markers (Gamma-glutamyltransferase)
direction: negative
category: healthcare_access
mechanism_pathway:
- 'Step 1: Topiramate reduces alcohol consumption more effectively than naltrexone'
- 'Step 2: Decreased alcohol intake reduces hepatotoxic exposure to ethanol and acetaldehyde'
- 'Step 3: Reduced liver inflammation and oxidative stress occurs with lower alcohol
  exposure'
- 'Step 4: Gamma-glutamyltransferase levels decrease as hepatocellular injury diminishes'
evidence:
  quality_rating: C
  n_studies: 1
  primary_citation: 'Kirsten C Morley et al. 2024. "Topiramate Versus Naltrexone for
    Alcohol Use Disorder: A Genotype-Stratified Double-Blind Randomized Controlled
    Trial.." *American Journal of Psychiatry*. https://doi.org/10.1176/appi.ajp.20230666'
last_updated: '2025-12-02'
version: '1.0'
llm_metadata:
  extracted_by: claude-sonnet-4-5-20250929
  extraction_date: '2025-12-02T18:12:06.665863'
  batch_id: msgbatch_01AKnPJgzm7Fk9qubgAz9GaD
_source_file: /Users/mauriceelhelou/Library/CloudStorage/OneDrive-HarvardUniversity/New
  folder (2)/healthsystems/mechanism-bank/mechanisms/healthcare_access/topiramate_treatment_to_liver_injury_markers.yaml
_category: healthcare_access
